Investor's Business Daily on MSN
Amgen sees RS rating improve to 71
Amgen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...
Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...
Investor's Business Daily on MSN
Stock market today: Dow dips as these gold stocks near entries; defense stock tests buy point (live coverage)
Stock Market Today: The Dow Jones index rose Monday. Tesla neared a buy point while President Trump edged closer to a Fed ...
Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, making it the ...
AI growth, margin strain, and intensifying chip rivalry are forcing investors to reassess this tech heavyweight, today, Dec.
Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility review, while analysts maintain confidence in Vyvgart's broader growth.
U.S. stock futures are up early Monday morning, following a mixed week that saw rotation out of expensive tech stocks in ...
It's hard to beat dividend-paying stocks -- in part because they tend to increase their payouts regularly.
Argenx SE shares fell the most in seven months after the biotech firm said it will discontinue late-stage trials for an experimental medicine to treat an autoimmune disease affecting the eyes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback